There are 2789 resources available
646TiP - A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
Presenter: Pierre Blanchard
Session: ePoster Display
648TiP - PSMAfore: A phase III study to compare <sup>177</sup>Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Presenter: Michael Morris
Session: ePoster Display
649TiP - PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer
Presenter: Boris Hadaschik
Session: ePoster Display
650TiP - PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa)
Presenter: Anuradha Jayaram
Session: ePoster Display
660P - Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Presenter: Toni Choueiri
Session: ePoster Display
661P - Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Presenter: Robert Motzer
Session: ePoster Display